Navigation Links
Valtrex Prevents the Need for C-Section among Women Infected With Genital Herpes

Researchers from the University of Texas, Southwestern Medical Center have found a new anti viral drug which prevents the necessity of a caesarean section //in pregnant woman who have a history of genital herpes.

The UT Southwestern study is the first large-scale confirmation that the drug valacyclovir hydrochloride (Valtrex) is effective in the last month of pregnancy, the researchers said.

The study appears in this month's issue of the journal Obstetrics and Gynecology. ‘I think this will help immensely in giving doctors stronger evidence in using this treatment,’ said Dr. Jeanne Sheffield, assistant professor of obstetrics and gynecology at UT Southwestern and lead author of the study. ‘Besides reducing the number of herpes outbreaks at birth, we also dropped the numbers of women without symptoms who were shedding the virus into the birth canal.’

Herpes, one of the most common sexually transmitted viral infections, causes periods of genital sores, followed by months or years of dormancy. It can't be cured, although the number and severity of outbreaks can be reduced through medication. Many women of reproductive age are unaware that they have the virus. In rare cases, infants can catch herpes simplex virus from the birth canal or genital region of the mother during birth, even when the mother isn't showing symptoms. Current medical protocol is to offer C-sections to all women with active genital herpes lesions at the time of delivery.

Nonetheless, 70 percent of neonatal herpes cases occur in infants of women who asymptomatically shed the virus near delivery, according to the researchers. ‘The whole goal of this study was to reduce active genital herpes lesions at delivery that require a Caesarean delivery to prevent neonatal herpes,’ Dr. Sheffield said. The UT Southwestern study, which involved 338 pregnant women with a history of genital herpes, was a randomized, double-blind trial, with neither the doctors nor the women knowing who was getting the medication. Twenty-eight women had C-sections because of active herpes lesions.

Seven of the 170 women in the valacyclovir group, or 4 percent, had the operation, while 21 of the 168 women in the placebo group, or 13 percent, had C-sections. The 69 percent reduction in the rate of clinical herpes simplex virus at the time of delivery was statistically significant, the researchers said. None of the babies in either group were born with herpes. There also were no differences in complications between the valacyclovir and placebo groups. ‘This work is a good example of a well-designed study that is of sufficient size to help clinicians and patients have confidence in the efficacy and safety of anti-viral suppression in late pregnancy,’ said Dr. George Wendel, professor of obstetrics and gynecology and senior author of the study.

Source: Eurealert

Related medicine news :

1. Tea Prevents Skin Cancer
2. Use Of Sunscreen In Childhood And Prevents Future Skin Cancer
3. Research Shows Carbon Monoxide Prevents Inflammations
4. Polluted Water Prevents Men From Getting Married
5. Rush Study Shows That Interactions with Friends and Family Prevents Damaging Effects of Alzheimers disease
6. Fitness Prevents Alzheimers
7. Vegetarian Diet Prevents the Development of Atherosclerosis
8. Exercise in Space Prevents Kidney Stone Formation in Astronauts
9. Study Says - Blocking aP2 Protein Prevents Airway Diseases
10. Naloxone Prevents Heroin Overdose
11. A Drug That Prevents Blindness
Post Your Comments:

(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology: